We bring you the latest news from the healthcare about the health care in the United Kingdom.

donderdag 25 januari 2018

Nature Reviews Cancer contents February 2018 Volume 18 Number 2 65-134

If you are unable to see the message below, click here to view.
Nature Reviews Cancer
npj Breast Cancer is an online-only, open access, multidisciplinary journal dedicated to publishing high-quality original research articles, reviews, editorials, commentaries, and hypothesis generating observations on all areas of breast cancer research. All content from the journal is now included in PubMed Central and PubMed. Part of the Nature Partner Journal series, published in partnership with the Breast Cancer Research Foundation.
February 2018 Volume 18 Number 2
Nature Reviews Cancer cover
2016 2-year Impact Factor 37.147 Journal Metrics 2-year Median 28
In this issue
Research Highlights
Also this month
 Featured article:
Targeting mutant p53 for efficient cancer therapy
Vladimir J. N. Bykov, Sofi E. Eriksson, Julie Bianchi & Klas G. Wiman


Recommend to library
Frontiers in Cancer Immunotherapy 
April 26-27, 2018

Keynote speakers Jeffrey Ravetch of The Rockefeller University and Miriam Merad of Mount Sinai School of Medicine join other top experts in oncology and immunology to discuss emerging approaches and challenges faced in this rapidly evolving field. Abstract deadline: Feb. 23rd. Find more information and register here.
Nature Outlook: Cancer immunotherapy 

Drugs that mobilize our immune systems against cancer are dramatically improving care for many people, and research is rapidly moving ahead in the lab and the clinic. 

Access this Outlook free >>

Produced with support from 
F. Hoffmann-La Roche Ltd

Produced with support of a grant from Merck & Co., Inc.
nature.com webcasts

Springer Nature presents a custom webcast on: Applications of imaging flow cytometry for the diagnosis of leukaemia

Date: Thursday, February 22, 2018 Time: 8AM PST | 11AM EST | 4PM GMT | 5PM CEST

Register for the webcast and live Q&A session

Sponsored by: 

Tumour microenvironment: Radical changes
p65 | doi:10.1038/nrc.2018.4
Reactive oxygen species derived from inflammatory myeloid cells is sufficient to induce mutagenesis in intestinal epithelial cells, independently of cytokines, to promote tumour initiation and progression.

Metabolism: Fusion power
p66 | doi:10.1038/nrc.2018.2
The fusion gene consisting of fibroblast growth factor receptor 3 and transforming acidic coiled-coil-containing protein 3 is oncogenic and present in a small cancer subset. Frattini et al. have identified that this fusion gene drives peroxisomal and mitochondrial biogenesis.

Oncogenes: Driving immune evasion
p67 | doi:10.1038/nrc.2018.5
Three recent papers have shed light on how the common oncogenic drivers MYC and RAS can induce an immunosuppressive tumour microenvironment.



Immunotherapy: Bad B cells | Tumour metabolism: The promoter becomes the suppressor | Gastric cancer: Risk analysis

Nature Reviews Cancer
JOBS of the week
Faculty Positions in Translational Sensory Neuroscience and Cancer
Creighton University School of Medicine, Department of Biomedical Sciences
Associate Director, Population Science (Cancer)
The Stanford Cancer Institute
Post Doctoral Researcher
The Ohio State University Comprehensive Cancer Center and Colleage of Medicine
Postdoctoral Scientist in Oncology
Johnson & Johnson Pharmaceutical Research & Development
Patient Specific iPS Cells for Studying Leukemia
Institute for Biomedical Engineering, Department of Cell Biology
More Science jobs from
Nature Reviews Cancer
4th World Congress on Cancer and Prevention Methods
Valencia, Spain
More science events from
Do you have a career question? 

The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud.

Listen today!
Ubiquitin ligases in oncogenic transformation and cancer therapy
Daniela Senft, Jianfei Qi & Ze'ev A. Ronai

p69 | doi:10.1038/nrc.2017.105
Ubiquitin ligases (E3s) participate in many cellular processes, including cell cycle progression and cell death. This Review by Senft et al. discusses how deregulation of E3s can lead to tumorigenesis and highlights the opportunities for targeting E3s as an anticancer therapy.
Abstract | Full Text | PDF | Supplementary information

Targeting mutant p53 for efficient cancer therapy
Vladimir J. N. Bykov, Sofi E. Eriksson, Julie Bianchi & Klas G. Wiman

p89 | doi:10.1038/nrc.2017.109
Inactivating mutations in the tumour suppressor gene TP53 are frequent in cancer. This Review provides a critical overview of reactivating p53 as a therapeutic strategy, describing preclinical and clinical compounds that re-establish the functions of wild-type p53 in tumours.
Abstract | Full Text | PDF

Nature Outlook: Bladder cancer 

After three decades without progress, there is now hope that we can move the needle on treating bladder cancer. 

Access the free Outlook >> 

Produced with support from: 
Autoimmunity checkpoints as therapeutic targets in B cell malignancies
Markus Muschen

p103 | doi:10.1038/nrc.2017.111
Recent studies have suggested that autoimmunity checkpoints (AICs) are fully functional in B cell leukaemias and lymphomas, despite malignant transformation. This Opinion article proposes that targeted engagement of AICs might represent a therapeutic opportunity to overcome drug resistance in B cell malignancies.
Abstract | Full Text | PDF

Differentiation therapy revisited
Hugues de The

p117 | doi:10.1038/nrc.2017.103
Differentiation therapy has shown great success in the treatment of acute promyelocytic leukaemia (APL). This Opinion article discusses the molecular basis for the success of APL treatment and the potential of drug-induced tumour cell differentiation in other malignancies.
Abstract | Full Text | PDF

EMT in cancer
Thomas Brabletz, Raghu Kalluri, M. Angela Nieto & Robert A. Weinberg

p128 | doi:10.1038/nrc.2017.118
In this Viewpoint article, we asked four scientists working in the field of epithelial to mesenchymal transition (EMT) to provide their opinions on the role of this complicated phenomenon in cancer biology as well as the challenges of this fast-moving field and the directions it should take in the future.
Abstract | Full Text | PDF

Corrigendum: Ribosome biogenesis in cancer: new players and therapeutic avenues
Joffrey Pelletier, George Thomas & Sinisa Volarevic

p134 | doi:10.1038/nrc.2018.3
Full Text | PDF
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature